Skandinaviska Enskilda Banken (SEB)
STRO icon

Skandinaviska Enskilda Banken (SEB)’s Sutro Biopharma STRO Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-510
Closed -$27K – 1019
2022
Q2 		$27K Hold
510
– – ﹤0.01% 981
2022
Q1 		$42K Buy
+510
New +$48.5K ﹤0.01% 959

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s STRO Position: Q3 2022 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Sutro Biopharma (STRO) in Q3 2022, closing a stake of 510 shares — an estimated $27K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in STRO in Q1 2022 and held it in 2 quarters. The position peaked at $42K in Q1 2022. 113 funds tracked by Wall St. Rank hold STRO as of Q3 2022.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Sutro Biopharma position as of Q3 2022 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 510 Sutro Biopharma shares in Q3 2022, an estimated $27K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Sutro Biopharma in Q1 2022 and held it in 2 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Sutro Biopharma position peaked at $42K in Q1 2022.
  • 113 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2022.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2022, filed 14 Nov 2022.